Literature DB >> 30053296

The Latent Human Immunodeficiency Virus (HIV) Reservoir Resides Primarily in CD32-CD4+ T Cells in Perinatally HIV-Infected Adolescents With Long-Term Virologic Suppression.

Adit Dhummakupt1, Lilly V Siems1, Dolly Singh1, Ya Hui Chen1, Thuy Anderson1, Aleisha Collinson-Streng1, Hao Zhang2, Purvish Patel3, Allison Agwu1, Deborah Persaud1.   

Abstract

Background: High-level expression of the Fcγ receptor, CD32hi, on CD4+ T cells was associated with enhanced human immunodeficiency virus (HIV) infection of the latent reservoir in a study of adults receiving antiretroviral therapy. We tested the hypothesis that CD32 was the preferential marker of the latent HIV reservoir in virally suppressed, perinatally HIV-infected adolescents.
Methods: The frequency of CD32hiCD4+ T cells was determined by flow cytometry (N = 5) and the inducible HIV reservoir in both CD32hi and CD32-CD4+ T cells was quantified (N = 4) with a quantitative viral outgrowth assay. Viral outgrowth was measured by the standard p24 enzyme-linked immunosorbent assay and an ultrasensitive p24 assay (Simoa; Quanterix) with lower limits of quantitation.
Results: We found a 59.55-fold enrichment in the absolute number of infectious cells in the CD32- population compared with CD32hi cells. Exponential HIV replication occurred exclusively in CD32-CD4+ T cells (mean change, 17.46 pg/mL; P = .04). Induced provirus in CD32hiCD4+ T cells replicated to substantially lower levels, which did not increase significantly over time (mean change, 0.026 pg/mL; P = .23) and were detected only with the Simoa assay. Conclusions: Our data suggests that the latent HIV reservoir resides mainly in CD32-CD4+ T cells in virally suppressed, perinatally HIV-infected adolescents, which has implications for reservoir elimination strategies.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30053296      PMCID: PMC6284548          DOI: 10.1093/infdis/jiy461

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  27 in total

1.  A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children.

Authors:  D Persaud; T Pierson; C Ruff; D Finzi; K R Chadwick; J B Margolick; A Ruff; N Hutton; S Ray; R F Siliciano
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Authors:  Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano
Journal:  Nat Med       Date:  2003-05-18       Impact factor: 53.440

3.  Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies.

Authors:  Amanda M Crooks; Rosalie Bateson; Anna B Cope; Noelle P Dahl; Morgan K Griggs; JoAnn D Kuruc; Cynthia L Gay; Joseph J Eron; David M Margolis; Ronald J Bosch; Nancie M Archin
Journal:  J Infect Dis       Date:  2015-04-15       Impact factor: 5.226

4.  Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals.

Authors:  Janet D Siliciano; Robert F Siliciano
Journal:  Methods Mol Biol       Date:  2005

5.  CD32 Expression of Different Memory T Cell Subpopulations in the Blood and Lymph Nodal Tissue of HIV Patients and Healthy Controls Correlates With Immune Activation.

Authors:  Melanie Wittner; Gábor A Dunay; Silke Kummer; Maximillian Bockhorn; Anja Hüfner; Stefan Schmiedel; Olaf Degen; Jan van Lunzen; Johanna M Eberhard; Julian Schulze Zur Wiesch
Journal:  J Acquir Immune Defic Syndr       Date:  2018-04-01       Impact factor: 3.731

6.  A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.

Authors:  S M Hammer; D A Katzenstein; M D Hughes; H Gundacker; R T Schooley; R H Haubrich; W K Henry; M M Lederman; J P Phair; M Niu; M S Hirsch; T C Merigan
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

7.  Human Immunodeficiency Virus Type 1 DNA Decay Dynamics With Early, Long-term Virologic Control of Perinatal Infection.

Authors:  Priyanka Uprety; Kunjal Patel; Brad Karalius; Carrie Ziemniak; Ya Hui Chen; Sean S Brummel; Suzanne Siminski; Russell B Van Dyke; George R Seage; Deborah Persaud
Journal:  Clin Infect Dis       Date:  2017-06-01       Impact factor: 9.079

8.  A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals.

Authors:  Francesco Andrea Procopio; Rémi Fromentin; Deanna A Kulpa; Jessica H Brehm; Anne-Gaelle Bebin; Matthew C Strain; Douglas D Richman; Una O'Doherty; Sarah Palmer; Frederick M Hecht; Rebecca Hoh; Richard J O Barnard; Michael D Miller; Daria J Hazuda; Steven G Deeks; Rafick-Pierre Sékaly; Nicolas Chomont
Journal:  EBioMedicine       Date:  2015-06-27       Impact factor: 8.143

9.  Towards an HIV cure.

Authors:  Steven Deeks
Journal:  J Int AIDS Soc       Date:  2014-11-02       Impact factor: 5.396

10.  CD32-Expressing CD4 T Cells Are Phenotypically Diverse and Can Contain Proviral HIV DNA.

Authors:  Genevieve E Martin; Matthew Pace; John P Thornhill; Chansavath Phetsouphanh; Jodi Meyerowitz; Morgane Gossez; Helen Brown; Natalia Olejniczak; Julianne Lwanga; Gita Ramjee; Pontiano Kaleebu; Kholoud Porter; Christian B Willberg; Paul Klenerman; Nneka Nwokolo; Julie Fox; Sarah Fidler; John Frater
Journal:  Front Immunol       Date:  2018-05-04       Impact factor: 7.561

View more
  3 in total

1.  Differences in inducibility of the latent HIV reservoir in perinatal and adult infection.

Authors:  Adit Dhummakupt; Jessica H Rubens; Thuy Anderson; Laura Powell; Bareng As Nonyane; Lilly V Siems; Aleisha Collinson-Streng; Tricia Nilles; R Brad Jones; Vicki Tepper; Allison Agwu; Deborah Persaud
Journal:  JCI Insight       Date:  2020-02-27

2.  Detection of Inducible Replication-Competent HIV-1 Subtype C Provirus Despite Long-Term Antiretroviral Treatment in Perinatally Infected Adolescents in Botswana.

Authors:  Catherine K Koofhethile; Sikhulile Moyo; Kenanao P Kotokwe; Charlotte Chang; Patrick Mokgethi; Lorato Muchoba; Selebogo Mokgweetsi; Joseph Makhema; Shahin Lockman; Simani Gaseitsiwe; Tulio de Oliveira; M Essex; Roger Shapiro; Phyllis Kanki; Vladimir Novitsky
Journal:  AIDS Res Hum Retroviruses       Date:  2020-10-19       Impact factor: 2.205

3.  In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells.

Authors:  Amanda G Tomalka; Ivelisse Resto-Garay; Kerry S Campbell; Daniel L Popkin
Journal:  Front Immunol       Date:  2018-11-05       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.